Status:

UNKNOWN

Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

Lead Sponsor:

Kidney Cancer Research Bureau

Conditions:

Renal Cell Carcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The aim of this Phase 2 study is to evaluate the efficacy and safety of nivolumab, an anti-PD-1 antibody, and ipilimumab, an anti-CTLA-4 antibody, in T1aN0M0 clear-cell RCC patients ineligible for sur...

Detailed Description

Surgery remains the standard curative-intent therapy for localized renal cell carcinoma (RCC). Thus, systemic therapy for RCC should still be considered only in patients who have contraindications to ...

Eligibility Criteria

Inclusion

  • Cytologically proven clear-cell RCC
  • CT-confirmed measurable primary tumor less than 4 cm and no evidence of extranodal metastatic disease (T1aN0M0)
  • Inability to perform surgery for any reason (functional single kidney with a central, high-complexity RCC, high risk of nephrectomy and dialysis, patients with complex coagulation disorders, etc.) or preference of patient is to have no surgery for any reason
  • No contradictions to nivolumab and ipilimumab
  • Age 18 or older
  • Written informed consent

Exclusion

  • prior treatment for RCC
  • pregnant or nursing
  • history of serious hypertension, cardiac arrhythmia, congestive heart failure, angina pectoris, or another severe cardiovascular disease (i.e., New York Heart Association class III or IV)
  • evidence of metastatic disease
  • local and/or systemic infections requiring antibiotics within 28 days prior to study entry
  • other malignancy

Key Trial Info

Start Date :

October 16 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2021

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT04134182

Start Date

October 16 2019

End Date

December 1 2021

Last Update

December 23 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

N.N. Blokhin Russian Cancer Research Center

Moscow, Russia

2

Russian Scientific Center of Roentgenoradiology

Moscow, Russia